Market research
SYRS Syros Pharmaceuticals Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3K
- P/E ratio
- Not available
- Analyst target
- 8.75
- Dividend yield
- Not available
- Beta
- 1.33
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US87184Q1076
- Market cap
- 3K
- P/E ratio
- Not available
- Analyst target
- 8.75
- Dividend yield
- Not available
- Beta
- 1.33
About
About Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SYRS discussion.
5 years, 4 months ago
Syros Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 37.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.8.
Syros Pharmaceuticals, Inc's total revenue rose by 1021.9% to $6M since the same quarter in the previous year.
Its net income has dropped by 52.7% to $-30M since the same quarter in the previous year.
Finally, its free cash flow fell by 59.7% to $-30M since the same quarter in the previous year.
Based on the above factors, Syros Pharmaceuticals, Inc gets an overall score of 2/5.